"Novo Nordisk's semaglutide has racked up several clinical wins demonstrating the GLP-1 receptor agonist's benefit goes beyond just weight loss, with the most recent data showing the drug can reduce mortality in patients with type 2 diabetes and chronic kidney disease, while earlier findings cemented its ability to reduce major adverse cardiovascular events.
Now, a new study suggests it may be able to help people who suffer from alcohol-use disorder (AUD)".
Read more: https://firstwordpharma.com/story/5861815
Now, a new study suggests it may be able to help people who suffer from alcohol-use disorder (AUD)".
Read more: https://firstwordpharma.com/story/5861815
Det kan jo kurere alt. Håber det også virker mod lommesmerter!
